Q1 FY 2027 saw 37% revenue and 39% EBITDA growth year-over-year, driven by semaglutide launches, capacity expansion, and new customer wins. Strong order book and capacity additions support reaffirmed FY 2028 guidance of INR 400 million revenue and 40% EBITDA margin.Based on OneSource Specialty Phar…
Q1 FY 2027 saw 37% revenue and 39% EBITDA growth year-over-year, driven by semaglutide launches, capacity expansion, and new customer wins. Strong order book and capacity additions support reaffirmed FY 2028 guidance of INR 400 million revenue and 40% EBITDA margin.
Based on
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
